Protagonist Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $18.75
- Today's High:
- $19.18
- Open Price:
- $18.79
- 52W Low:
- $7.235
- 52W High:
- $30.1
- Prev. Close:
- $18.86
- Volume:
- 344807
Company Statistics
- Market Cap.:
- $1.09 billion
- Book Value:
- 5.115
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $26.58 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -29.16%
- Return on Equity TTM:
- -48.97%
Company Profile
Protagonist Therapeutics Inc had its IPO on 2016-08-11 under the ticker symbol PTGX.
The company operates in the Healthcare sector and Biotechnology industry. Protagonist Therapeutics Inc has a staff strength of 106 employees.
Stock update
Shares of Protagonist Therapeutics Inc opened at $18.79 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $18.75 - $19.18, and closed at $18.81.
This is a -0.27% slip from the previous day's closing price.
A total volume of 344,807 shares were traded at the close of the day’s session.
In the last one week, shares of Protagonist Therapeutics Inc have slipped by -3.74%.
Protagonist Therapeutics Inc's Key Ratios
Protagonist Therapeutics Inc has a market cap of $1.09 billion, indicating a price to book ratio of 1.9246 and a price to sales ratio of 13.2717.
In the last 12-months Protagonist Therapeutics Inc’s revenue was $0 with a gross profit of $26.58 million and an EBITDA of $-146183008. The EBITDA ratio measures Protagonist Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Protagonist Therapeutics Inc’s operating margin was 0% while its return on assets stood at -29.16% with a return of equity of -48.97%.
In Q2, Protagonist Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Protagonist Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-2.57 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Protagonist Therapeutics Inc’s profitability.
Protagonist Therapeutics Inc stock is trading at a EV to sales ratio of 5.843 and a EV to EBITDA ratio of -1.6038. Its price to sales ratio in the trailing 12-months stood at 13.2717.
Protagonist Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $320.47 million
- Total Liabilities
- $26.40 million
- Operating Cash Flow
- $25.76 million
- Capital Expenditure
- $176000
- Dividend Payout Ratio
- 0%
Protagonist Therapeutics Inc ended 2024 with $320.47 million in total assets and $0 in total liabilities. Its intangible assets were valued at $320.47 million while shareholder equity stood at $294.07 million.
Protagonist Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $26.40 million in other current liabilities, 1000.00 in common stock, $-608940000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $235.38 million and cash and short-term investments were $313.40 million. The company’s total short-term debt was $2,446,000 while long-term debt stood at $0.
Protagonist Therapeutics Inc’s total current assets stands at $316.94 million while long-term investments were $0 and short-term investments were $78.02 million. Its net receivables were $50000.00 compared to accounts payable of $4.57 million and inventory worth $-50000.00.
In 2024, Protagonist Therapeutics Inc's operating cash flow was $25.76 million while its capital expenditure stood at $176000.
Comparatively, Protagonist Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $18.81
- 52-Week High
- $30.1
- 52-Week Low
- $7.235
- Analyst Target Price
- $39.6
Protagonist Therapeutics Inc stock is currently trading at $18.81 per share. It touched a 52-week high of $30.1 and a 52-week low of $30.1. Analysts tracking the stock have a 12-month average target price of $39.6.
Its 50-day moving average was $19.91 and 200-day moving average was $19.09 The short ratio stood at 4.45 indicating a short percent outstanding of 0%.
Around 166.4% of the company’s stock are held by insiders while 9622.2% are held by institutions.
Frequently Asked Questions About Protagonist Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.